Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

Abstract excerpt

BACKGROUND & AIMS: To assess the risk for the development of hepatocellular carcinoma (HCC) according to the underlying liver status and on-treatment viral response during long-term lamivudine therapy in patients with hepatitis B virus-related liver disease. PATIENTS AND METHODS: Between March 1997 and February 2005, a total of 872 patients were treated with lamivudine for more than one year. Between 1983 and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiviral Agents
• Share to Carcinoma, Hepatocellular